Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition.
cannabidiol
cognition
endocannabinoid system
psychosis
Δ-9-tetrahydrocannabinol
Journal
Frontiers in psychology
ISSN: 1664-1078
Titre abrégé: Front Psychol
Pays: Switzerland
ID NLM: 101550902
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
01
2020
accepted:
03
04
2020
entrez:
13
6
2020
pubmed:
13
6
2020
medline:
13
6
2020
Statut:
epublish
Résumé
Research evidence suggests a dose-response relationship for the association between cannabis use and risk of psychosis. Such relationship seems to reflect an increased risk of psychosis not only as a function of frequent cannabis use, but also of high-potency cannabis use in terms of concentration of Δ-9-tetrahydrocannabinol (Δ9-THC), its main psychoactive component. This finding would be in line with the evidence that Δ9-THC administration induces transient psychosis-like symptoms in otherwise healthy individuals. Conversely, low-potency varieties would be less harmful because of their lower amount of Δ9-THC and potential compresence of another cannabinoid, cannabidiol (CBD), which seems to mitigate Δ9-THC detrimental effects. A growing body of studies begins to suggest that CBD may have not only protective effects against the psychotomimetic effects of Δ9-THC but even therapeutic properties on its own, opening new prospects for the treatment of psychosis. Despite being more limited, evidence of the effects of cannabis on cognition seems to come to similar conclusions, with increasing Δ9-THC exposure being responsible for the cognitive impairments attributed to recreational cannabis use while CBD preventing such effects and, when administered alone, enhancing cognition. Molecular evidence indicates that Δ9-THC and CBD may interact with cannabinoid receptors with almost opposite mechanisms, with Δ9-THC being a partial agonist and CBD an inverse agonist/antagonist. With the help of imaging techniques, pharmacological studies
Identifiants
pubmed: 32528345
doi: 10.3389/fpsyg.2020.00833
pmc: PMC7247841
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
833Subventions
Organisme : Medical Research Council
ID : MC_PC_14105
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J012149/1
Pays : United Kingdom
Informations de copyright
Copyright © 2020 Colizzi, Ruggeri and Bhattacharyya.
Références
JAMA Psychiatry. 2016 Nov 1;73(11):1173-1179
pubmed: 27680429
Schizophr Res. 2016 Mar;171(1-3):62-7
pubmed: 26785806
Arch Gen Psychiatry. 2012 Jan;69(1):27-36
pubmed: 22213786
Psychol Med. 2018 Oct;48(14):2346-2352
pubmed: 29382407
Psychopharmacology (Berl). 2002 Oct;164(1):61-70
pubmed: 12373420
Br J Psychiatry. 2006 Jun;188:519-26
pubmed: 16738341
Exp Clin Psychopharmacol. 2018 Dec;26(6):582-598
pubmed: 30138003
Nat Prod Rep. 2016 Nov 23;33(12):1357-1392
pubmed: 27722705
Biol Psychiatry. 2005 Mar 15;57(6):594-608
pubmed: 15780846
Am J Epidemiol. 2002 Aug 15;156(4):319-27
pubmed: 12181101
Mol Psychiatry. 2012 Dec;17(12):1152-5
pubmed: 22290123
Schizophr Bull. 2016 Sep;42(5):1262-9
pubmed: 26884547
Psychol Med. 2014 Dec;44(16):3435-44
pubmed: 25066001
Drug Alcohol Depend. 2014 Nov 1;144:12-41
pubmed: 25220897
J Neurosci. 2019 Oct 16;39(42):8250-8258
pubmed: 31619494
PLoS One. 2013 Oct 24;8(10):e76635
pubmed: 24204649
JAMA Psychiatry. 2018 Nov 1;75(11):1107-1117
pubmed: 30167644
J Psychopharmacol. 2009 Nov;23(8):979-83
pubmed: 18801821
J Addict Res Ther. 2013 Apr 24;Suppl 4:
pubmed: 24587965
Hum Psychopharmacol. 2013 Jul;28(4):379-89
pubmed: 23881886
Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):E500-8
pubmed: 26787878
BMC Neurosci. 2012 Feb 15;13:18
pubmed: 22336227
Front Psychiatry. 2019 Feb 19;10:63
pubmed: 30837904
J Clin Psychiatry. 1995 Oct;56(10):485-6
pubmed: 7559378
BMJ. 2002 Nov 23;325(7374):1212-3
pubmed: 12446537
Neurotherapeutics. 2015 Oct;12(4):699-730
pubmed: 26264914
Neuropsychopharmacology. 2015 May;40(6):1343-52
pubmed: 25249057
Br J Pharmacol. 2008 Jan;153(2):199-215
pubmed: 17828291
Eur Neuropsychopharmacol. 2015 Jan;25(1):26-37
pubmed: 25532865
Lancet. 1987 Dec 26;2(8574):1483-6
pubmed: 2892048
Psychol Med. 2016 Mar;46(4):841-54
pubmed: 26610039
BMJ. 2019 Apr 4;365:l1141
pubmed: 30948383
Lancet Psychiatry. 2015 Mar;2(3):233-8
pubmed: 26359901
Eur Neuropsychopharmacol. 2018 Jul;28(7):850-862
pubmed: 29935939
Psychopharmacology (Berl). 2019 Dec 9;:
pubmed: 31814047
Exp Clin Psychopharmacol. 2012 Oct;20(5):420-429
pubmed: 22731735
Int J Mol Sci. 2018 Mar 13;19(3):
pubmed: 29533978
Eur Neuropsychopharmacol. 2015 Mar;25(3):325-34
pubmed: 25534187
Neurosci Biobehav Rev. 2018 May;88:26-41
pubmed: 29535069
Biol Psychiatry. 2016 Apr 1;79(7):595-603
pubmed: 26210060
Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3216-28
pubmed: 23108541
Brain Sci. 2019 Apr 25;9(4):
pubmed: 31027219
Br J Pharmacol. 2015 Oct;172(20):4790-805
pubmed: 26218440
Biol Psychiatry. 2016 Apr 1;79(7):516-25
pubmed: 26698193
Curr Pharm Des. 2012;18(32):5045-54
pubmed: 22716136
Addiction. 2012 Jun;107(6):1174-84
pubmed: 22151745
Addiction. 2005 May;100(5):612-8
pubmed: 15847618
Psychopharmacology (Berl). 2018 Jul;235(7):1923-1932
pubmed: 29619533
Braz J Psychiatry. 2019 Jan-Mar;41(1):9-14
pubmed: 30328956
Psychol Med. 2018 Dec;48(16):2748-2756
pubmed: 29502548
Physiol Rev. 2009 Jan;89(1):309-80
pubmed: 19126760
Br J Psychiatry. 2010 Oct;197(4):285-90
pubmed: 20884951
J Psychopharmacol. 2006 Sep;20(5):683-6
pubmed: 16401651
BMJ. 2002 Nov 23;325(7374):1199
pubmed: 12446534
Neuropharmacology. 2017 Sep 15;124:89-104
pubmed: 28634109
Psychol Med. 2003 Jan;33(1):15-21
pubmed: 12537032
Nat Rev Neurosci. 2015 Jan;16(1):30-42
pubmed: 25524120
Nature. 1993 Sep 2;365(6441):61-5
pubmed: 7689702
Schizophr Res. 2015 Oct;168(1-2):185-90
pubmed: 26359848
Addict Biol. 2019 Sep 2;:e12827
pubmed: 31478302
Psychol Med. 2014 Nov;44(15):3315-28
pubmed: 25065544
Br J Psychiatry. 2018 Apr;212(4):195-196
pubmed: 29557759
JAMA Psychiatry. 2018 Jun 1;75(6):585-595
pubmed: 29710074
Br J Pharmacol. 2007 Mar;150(5):613-23
pubmed: 17245363
Br J Psychiatry. 2010 Jun;196(6):447-53
pubmed: 20513854
Biochem Pharmacol. 1995 Jun 29;50(1):83-90
pubmed: 7605349
Front Immunol. 2018 Sep 21;9:2009
pubmed: 30298064
J Psychopharmacol. 2016 Feb;30(2):140-51
pubmed: 26577065
Lancet Psychiatry. 2016 Oct;3(10):947-953
pubmed: 27567467
Neurobiol Aging. 2005 May;26(5):665-72
pubmed: 15708441
Science. 1992 Dec 18;258(5090):1946-9
pubmed: 1470919
JAMA Psychiatry. 2013 Jan;70(1):107-20
pubmed: 23165428
JAMA Psychiatry. 2019 Jun 5;:
pubmed: 31166595
Br J Pharmacol. 2007 Nov;152(5):583-93
pubmed: 17641667
Eur Neuropsychopharmacol. 2015 Aug;25(8):1201-24
pubmed: 26068702
Am J Psychiatry. 2016 Aug 1;173(8):781-9
pubmed: 27138587
Sci Rep. 2017 Nov 3;7(1):15025
pubmed: 29101333
Neuropsychopharmacology. 2010 Feb;35(3):764-74
pubmed: 19924114
Transl Psychiatry. 2019 Aug 22;9(1):203
pubmed: 31439831
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657-64
pubmed: 22927402
JAMA Psychiatry. 2017 Jun 1;74(6):579-588
pubmed: 28445557
Expert Opin Emerg Drugs. 2009 Mar;14(1):43-65
pubmed: 19249987
Curr Addict Rep. 2017;4(2):62-74
pubmed: 28580227
Mol Psychiatry. 2019 Feb 15;:
pubmed: 30770892
Front Public Health. 2018 Jun 07;6:162
pubmed: 29930934
Neurosci Biobehav Rev. 2019 Jan;96:45-55
pubmed: 30395923
F1000 Med Rep. 2013;5:1
pubmed: 23361396
Am J Psychiatry. 2004 Jun;161(6):975-84
pubmed: 15169685
Curr Drug Abuse Rev. 2012 Mar;5(1):32-40
pubmed: 22150622
BMJ. 2005 Jan 1;330(7481):11
pubmed: 15574485
Psychol Med. 2019 Aug 19;:1-10
pubmed: 31422779
J Psychopharmacol. 2010 Jan;24(1):135-7
pubmed: 18801823
Molecules. 2018 May 20;23(5):
pubmed: 29783790
Addiction. 2016 Oct;111(10):1764-73
pubmed: 27082374
JAMA. 2015 Jun 23-30;313(24):2456-73
pubmed: 26103030
Lancet Psychiatry. 2019 Dec;6(12):995-1010
pubmed: 31672337
Neuropsychopharmacology. 2004 Aug;29(8):1558-72
pubmed: 15173844
Braz J Psychiatry. 2010 Mar;32(1):56-61
pubmed: 20339735
Neurosci Biobehav Rev. 2018 Oct;93:1-25
pubmed: 30056176
Br J Pharmacol. 2015 Feb;172(3):737-53
pubmed: 25257544
Drug Metab Rev. 2018 Feb;50(1):3-13
pubmed: 29355030
Biol Psychiatry. 2016 Apr 1;79(7):539-48
pubmed: 26970364
MMWR Morb Mortal Wkly Rep. 2015 Jun 12;64(22):618-9
pubmed: 26068566
Am J Med Genet. 2002 Dec 8;114(8):949-55
pubmed: 12457392
J Nerv Ment Dis. 1990 Aug;178(8):473-80
pubmed: 2380692
Ther Adv Psychopharmacol. 2019 Nov 08;9:2045125319881916
pubmed: 31741731
Br J Psychiatry. 2015 Jan;206(1):77-8
pubmed: 25431432
Neurosci Biobehav Rev. 2016 May;64:359-81
pubmed: 26987641
J Neuroimmune Pharmacol. 2018 Dec;13(4):438-452
pubmed: 29556883
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
Psychol Med. 2020 Jan 29;:1-11
pubmed: 31994476
Nat Med. 2017 Jun;23(6):782-787
pubmed: 28481360
Curr Psychiatry Rep. 2016 Feb;18(2):12
pubmed: 26781550
Neurotherapeutics. 2015 Oct;12(4):735-46
pubmed: 26269228
Exp Clin Psychopharmacol. 2019 Oct 31;:
pubmed: 31670548
Lancet Psychiatry. 2019 May;6(5):427-436
pubmed: 30902669
Psychopharmacology (Berl). 2020 Apr;237(4):1121-1130
pubmed: 31915861
Prog Brain Res. 2018;242:179-216
pubmed: 30471680
Schizophr Res. 2016 Feb;170(2-3):311-7
pubmed: 26718334
Cortex. 2016 Aug;81:231-8
pubmed: 27261878
J Psychopharmacol. 2015 Feb;29(2):97-115
pubmed: 25586400
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):17-35
pubmed: 30661105
Psychol Med. 2012 Feb;42(2):391-400
pubmed: 21798112
Am J Psychiatry. 2018 Mar 1;175(3):225-231
pubmed: 29241357
Curr Pharm Des. 2016;22(42):6380-6391
pubmed: 27568729
Psychol Med. 2016 Jan;46(1):177-88
pubmed: 26353818
Transl Psychiatry. 2012 Mar 20;2:e94
pubmed: 22832859
Arch Gen Psychiatry. 2009 Apr;66(4):442-51
pubmed: 19349314
Psychol Med. 2012 Jun;42(6):1321-8
pubmed: 21999906
Nature. 1990 Aug 9;346(6284):561-4
pubmed: 2165569